Protective effect of quinacrine on striatal dopamine levels in 6-OHDA and MPTP models of Parkinsonism in rodents

[1]  R. Staudinger,et al.  Positive heterotropic allosteric regulators of dihydropyridine binding increase the Ca2+ affinity of the L-type Ca2+ channel. Stereoselective reversal by the novel Ca2+ antagonist BM 20.1140. , 1991, The Journal of biological chemistry.

[2]  M. Beal,et al.  NMDA antagonists partially protect against MPTP induced neurotoxicity in mice , 1993, Neuroreport.

[3]  P. Löschmann,et al.  Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists , 1991, Nature.

[4]  D. Alliangana.  Effects of beta-carotene, flavonoid quercitin and quinacrine on cell proliferation and lipid peroxidation breakdown products in BHK-21 cells. , 1996, East African medical journal.

[5]  H. Allain,et al.  Progress in Understanding the Pathophysiology of Cerebral Ischemia: The Almitrine‐Raubasine Approach , 1990, Clinical neuropharmacology.

[6]  S. Berger,et al.  Evidence for the involvement of phospholipase A2 mechanisms in the development of stimulant sensitization. , 1996, The Journal of pharmacology and experimental therapeutics.

[7]  C. Tagesson,et al.  Lysophosphatidylcholine and the inflammatory action of neutrophils. , 1988, Scandinavian journal of clinical and laboratory investigation.

[8]  C. Mytilineou,et al.  Basic Fibroblast Growth Factor Stimulation of Glial Cells Protects Dopamine Neurons from 6‐Hydroxydopamine Toxicity: Involvement of the Glutathione System , 1997, Journal of neurochemistry.

[9]  P. Bédard,et al.  Intranigral but not intrastriatal microinjection of the NMDA antagonist MK-801 induces contralateral circling in the 6-OHDA rat model , 1994, Brain Research.

[10]  M. Topilsky,et al.  Quinacrine inhibits oxygen radicals release from human alveolar macrophages. , 1992, International journal of immunopharmacology.

[11]  R. Butterworth,et al.  Hypokinesia produced by anterolateral hypothalamic 6-hydroxydopamine lesions and its reversal by some antiparkinson drugs , 1978, Pharmacology Biochemistry and Behavior.

[12]  Jeffrey C. Erlich,et al.  Increased phospholipid breakdown in schizophrenia. Evidence for the involvement of a calcium-independent phospholipase A2. , 1997, Archives of general psychiatry.

[13]  H. Przuntek,et al.  Effects of nimodipine on the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced depletions in the biogenic amine levels in mice. , 1993, Arzneimittel-Forschung.

[14]  F. Dorandeu,et al.  Secreted phospholipase A2‐induced neurotoxicity and epileptic seizures after intracerebral administration: An unexplained heterogeneity as emphasized with paradoxin and crotoxin , 1998, Journal of neuroscience research.

[15]  W. Gattaz,et al.  Intracerebroventricular injection of phospholipase A2 inhibits apomorphine-induced locomotion in rats , 1995, Psychiatry Research.

[16]  O. Griffith,et al.  Determination of glutathione and glutathione disulfide using glutathione reductase and 2-vinylpyridine. , 1980, Analytical biochemistry.

[17]  P. Riederer,et al.  Molecular mechanisms for neurodegeneration. Synergism between reactive oxygen species, calcium, and excitotoxic amino acids. , 1996, Advances in neurology.

[18]  I. Kaufmann,et al.  Enhanced biotransformation of nitrofurantoin in rats after induction with 3-methylcholanthrene or beta-naphthoflavone. , 1980, Biochemical pharmacology.

[19]  M. Kindt,et al.  Prevention of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic toxicity in mice by MDL 72145, a selective inhibitor of MAO-B. , 1986, Life sciences.

[20]  A. Kupsch,et al.  Pretreatment with nimodipine prevents MPTP-induced neurotoxicity at the nigral, but not at the striatal level in mice. , 1995, Neuroreport.

[21]  F. Vaglini,et al.  (+)MK-801 prevents the DDC-induced enhancement of MPTP toxicity in mice , 1994, Brain Research.

[22]  C. Rebert,et al.  Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey , 1984, Brain Research.

[23]  O. Andreassen,et al.  Mice Deficient in Group IV Cytosolic Phospholipase A2 Are Resistant to MPTP Neurotoxicity , 1998, Journal of neurochemistry.

[24]  I. Irwin,et al.  Diethyldithiocarbamate Causes Nigral Cell Loss and Dopamine Depletion with Nontoxic Doses of MPTP , 1999, Experimental Neurology.

[25]  D. Selkoe,et al.  Cytosolic Phospholipase A2(cPLA2) Immunoreactivity Is Elevated in Alzheimer's Disease Brain , 1996, Neurobiology of Disease.

[26]  T. H. Burnstine,et al.  Movement Disorders 2 , 1988, Neurology.

[27]  L. Forno.  Pathology of Parkinson's disease , 1981 .

[28]  S. Lipton.  AIDS‐Related Dementia and Calcium Homeostasis a , 1994, Annals of the New York Academy of Sciences.

[29]  T. Oishi,et al.  Sulfhydryl drugs reduce neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridime (MPTP) in the mouse , 1993, Journal of neural transmission. Parkinson's disease and dementia section.

[30]  M. Murakami,et al.  Function of type II phospholipase A2 in dopamine secretion by rat neuronal PC12 cells. , 1996, Journal of lipid mediators and cell signalling.

[31]  C. J. Moore,et al.  Phospholipase A2 activation influences the processing and secretion of the amyloid precursor protein. , 1993, Biochemical and biophysical research communications.

[32]  H. Miyake,et al.  Central nervous system bioaminergic responses to mechanical trauma. An experimental study. , 1991, Surgical neurology.

[33]  J. Phillis,et al.  Arachidonic acid and lysophosphatidylcholine modulate excitatory transmitter amino acid release from the rat cerebral cortex , 1995, Neuroscience Letters.

[34]  M. Kawai,et al.  Protective effects of pergolide on dopamine levels in the 6-hydroxydopamine-lesioned mouse brain. , 1995, Archives internationales de pharmacodynamie et de therapie.

[35]  Y. Goshima,et al.  Evaluation of a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated C57 black mouse model for parkinsonism , 1990, Brain Research.

[36]  N. Bazan,et al.  Mediators of injury in neurotrauma: intracellular signal transduction and gene expression. , 1995, Journal of neurotrauma.

[37]  Andrew C Talk,et al.  Phospholipases and arachidonic acid contribute independently to sensory transduction and associative neuronal facilitation in Hermissenda type B photoreceptors , 1997, Brain Research.

[38]  I. Mitchell,et al.  Reversal of Parkinsonian symptoms in primates by antagonism of excitatory amino acid transmission: Potential mechanisms of action , 1997, Neuroscience & Biobehavioral Reviews.

[39]  J. Cadet,et al.  Long-term behavioral and biochemical effects of 6-hydroxydopamine injections in rat caudate-putamen , 1991, Brain Research Bulletin.

[40]  A. K. Agarwal,et al.  Free Radical‐Generated Neurotoxicity of 6‐Hydroxydopamine , 1995, Journal of neurochemistry.

[41]  D. Togasaki,et al.  Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by instrastriatal injection of 6-hydroxydopamine , 1995, Neuroscience.

[42]  T. Heffner,et al.  The effect of water-deprivation on locomotor activity in rats treated with 6-hydroxydopamine , 1985, Brain Research.

[43]  L. Horrocks,et al.  Involvement of phospholipase A2 in neurodegeneration , 1997, Neurochemistry International.

[44]  O. Brørs,et al.  Inhibition by amiloride and quinacrine of specific [3H]nitrendipine binding to rat cardiac membranes. , 1992, The Journal of pharmacology and experimental therapeutics.

[45]  R. Ramsay,et al.  Biochemical Events in the Development of Parkinsonism Induced by 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine , 1987, Journal of neurochemistry.

[46]  M. da Prada,et al.  Ro 16-6491: a new reversible and highly selective MAO-B inhibitor protects mice from the dopaminergic neurotoxicity of MPTP. , 1987, Advances in neurology.

[47]  M. Beal,et al.  Elevation of neuronal MAO-B activity in a transgenic mouse model does not increase sensitivity to the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) , 1994, Brain Research.

[48]  J. Phillis,et al.  The phospholipase A2 inhibitor, quinacrine, reduces infarct size in rats after transient middle cerebral artery occlusion , 1997, Brain Research.

[49]  T. Klockgether,et al.  Differential interaction of competitive NMDA and AMPA antagonists with selective dopamine D‐1 and D‐2 agonists in a rat model of Parkinson's disease , 1997, Synapse.

[50]  J. Cadet,et al.  Regional effects of 6-hydroxydopamine (6-OHDA) on free radical scavengers in rat brain , 1989, Brain Research.

[51]  J. Cadet,et al.  Vitamin E attenuates the toxic effects of intrastriatal injection of 6-hydroxydopamine (6-OHDA) in rats: Behavioral and biochemical evidence , 1989, Brain Research.

[52]  J. D. Parkes,et al.  Fluctuations of disability in Parkinson's disease – clinical aspects , 1981 .

[53]  W. Cui,et al.  Effects of nicotine on 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine-induced depression of striatal dopamine content and spontaneous locomotor activity in C57 black mice. , 1998, Pharmacological research.

[54]  Annette M. Schmid,et al.  Glutathione depletion potentiates MPTP and MPP+ toxicity in nigral dopaminergic neurones , 1996, Neuroreport.

[55]  J. Phillis.  Cerebroprotective action of the phospholipase inhibitor quinacrine in the ischemia/reperfused gerbil hippocampus. , 1996, Life sciences.

[56]  P. Piper,et al.  Mechanisms of inhibition of phospholipase A2. , 1980, Biochemical pharmacology.

[57]  W. Young.  Role of calcium in central nervous system injuries. , 1992, Journal of neurotrauma.

[58]  G. Breese,et al.  Effect of 6-hydroxydopamine on brain norepinephrine and dopamine evidence for selective degeneration of catecholamine neurons. , 1970, The Journal of pharmacology and experimental therapeutics.

[59]  J. Phillis,et al.  A possible role for phospholipases in the release of neurotransmitter amino acids from ischemic rat cerebral cortex , 1995, Neuroscience Letters.

[60]  H. Khan,et al.  Dipyridamole potentiates 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced experimental Parkinsonism in mice. , 1998, Parkinsonism & related disorders.

[61]  J. Cadet,et al.  Vitamin E attenuates the toxic effects of 6-hydroxydopamine on free radical scavenging systems in rat brain , 1992, Brain Research Bulletin.

[62]  T. Klockgether,et al.  Excitatory amino acids and the basal ganglia: implications for the therapy of Parkinson's disease , 1989, Trends in Neurosciences.

[63]  R. Bartrons,et al.  Chronic effects of single intrastriatal injections of 6-hydroxydopamine or 1-methyl-4-phenylpyridinium studied by microdialysis in freely moving rats , 1995, Brain Research.

[64]  A. Benabid,et al.  Unlike MPP+, apoptosis induced by 6-OHDA in PC12 cells is independent of mitochondrial inhibition , 1996, Neuroscience Letters.

[65]  K. Ossowska.  The role of excitatory amino acids in experimental models of Parkinson's disease , 1994, Journal of neural transmission. Parkinson's disease and dementia section.

[66]  Y. Hannun,et al.  Role of phospholipases in generating lipid second messengers in signal transduction 1 , 1991, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[67]  P. Sonsalla,et al.  Some features of the nigrostriatal dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse. , 1989, Molecular and chemical neuropathology.

[68]  D. Stephenson,et al.  Reactive glia express cytosolic phospholipase A2 after transient global forebrain ischemia in the rat. , 1996, Stroke.

[69]  S. Toyoshima,et al.  Damage to mitochondrial respiration chain is related to phospholipase A2 activation caused by tumor necrosis factor. , 1992, Journal of immunotherapy : official journal of the Society for Biological Therapy.

[70]  G. Paxinos,et al.  The Rat Brain in Stereotaxic Coordinates , 1983 .

[71]  S J Kish,et al.  Biochemical pathophysiology of Parkinson's disease. , 1987, Advances in neurology.

[72]  M. Samochocki,et al.  Regulation of arachidonic acid release by enzyme(s) of rat brain cortex. , 1990, Acta biochimica Polonica.

[73]  C. Chiueh,et al.  Role of dopamine autoxidation, hydroxyl radical generation, and calcium overload in underlying mechanisms involved in MPTP-induced parkinsonism. , 1993, Advances in neurology.